MedTrace Logo

Regulatory AVAMYS Nasal Spray PMS

NCT01001130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3244

Last updated 2014-06-30

No results posted yet for this study

Summary

Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of AVAMYS nasal spray administered in Korean patients according to the prescribing information.

AVAMYS is a registered trademark of the GSK group of companies.

Conditions

  • Rhinitis, Allergic, Perennial and Seasonal

Interventions

DRUG

fluticasone furoate group

patients who are administered fluticasone furoate at least once

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001130 on ClinicalTrials.gov